Pharmaids [PHARMAID] vs Suven Life Sciences [SUVEN] Detailed Stock Comparison

Pharmaids

BSE
Loading...

Suven Life Sciences

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Pharmaids wins in 10 metrics, Suven Life Sciences wins in 8 metrics, with 0 ties. Pharmaids appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricPharmaidsSuven Life SciencesBetter
P/E Ratio (TTM)2,023.33-28.31Suven Life Sciences
Price-to-Book Ratio3.3541.36Pharmaids
Debt-to-Equity Ratio70.810.00Suven Life Sciences
PEG Ratio23.66-0.34Suven Life Sciences
EV/EBITDA-16.22-24.12Suven Life Sciences
Profit Margin (TTM)-61.01%84.44%Suven Life Sciences
Operating Margin (TTM)-90.28%-2,791.92%Pharmaids
Return on Equity-19.58%-146.15%Pharmaids
Return on Assets (TTM)-8.99%-118.91%Pharmaids
Free Cash Flow (TTM)$-264.72M$-1.91BPharmaids
1-Year Return30.67%45.95%Suven Life Sciences
Price-to-Sales Ratio (TTM)9.25632.35Pharmaids
Enterprise Value$2.35B$44.90BSuven Life Sciences
EV/Revenue Ratio10.98597.31Pharmaids
Gross Profit Margin (TTM)47.39%100.00%Suven Life Sciences
Revenue per Share (TTM)$6$0Pharmaids
Earnings per Share (Diluted)$-3.71$-8.45Pharmaids
Beta (Stock Volatility)0.530.78Pharmaids
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Pharmaids vs Suven Life Sciences Stock Performance Analysis

Loading Price Chart...

Pharmaids
Suven Life Sciences
Pharmaids Stock Overview | Suven Life Sciences Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Pharmaids-5.46%-12.16%-14.88%-8.85%-19.65%-29.42%
Suven Life Sciences-1.77%0.30%-12.23%-23.53%72.40%60.12%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Pharmaids30.67%281.24%550.44%1,134.75%1,482.73%125.13%
Suven Life Sciences45.95%208.80%320.60%-27.74%585.05%3,721.46%

News Based Sentiment: Pharmaids vs Suven Life Sciences

Pharmaids

News based Sentiment: MIXED

September brought substantial changes to Pharmaids Pharmaceuticals, including a major divestiture and an ongoing open offer, alongside continued financial difficulties. These events create both opportunities and risks for investors, making it a significant month for the company's trajectory. The mixed signals from insider trading add to the complexity of the investment picture.

View Pharmaids News Sentiment Analysis

Suven Life Sciences

News based Sentiment: MIXED

October was a month of conflicting signals for Suven Life Sciences. While the company benefited from a positive pharmaceutical sector rally and maintained a debt-free status, it also reported continued quarterly losses and received a negative analyst rating. This creates a complex investment narrative with both potential opportunities and significant risks.

View Suven Life Sciences News Sentiment Analysis

Performance & Financial Health Analysis: Pharmaids vs Suven Life Sciences

MetricPHARMAIDSUVEN
Market Information
Market Cap i₹1.98B₹47.99B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i4,989184,111
90 Day Avg. Volume i4,937150,383
Last Close₹49.38₹201.20
52 Week Range₹45.50 - ₹84.97₹102.50 - ₹299.99
% from 52W High-41.89%-32.93%
All-Time High₹87.46 (Nov 11, 2024)₹338.50 (Apr 13, 2015)
% from All-Time High-43.54%-40.56%
Growth Metrics
Quarterly Revenue Growth0.43%0.86%
Quarterly Earnings Growth0.43%0.86%
Financial Health
Profit Margin (TTM) i-0.61%0.84%
Operating Margin (TTM) i-0.90%-27.92%
Return on Equity (TTM) i-0.20%-1.46%
Debt to Equity (MRQ) i70.810.00
Cash & Liquidity
Book Value per Share (MRQ)₹16.72₹5.04
Cash per Share (MRQ)₹0.61₹2.75
Operating Cash Flow (TTM) i₹-278,094,000₹-1,590,282,000
Levered Free Cash Flow (TTM) i₹-107,766,000₹-1,607,450,000
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/A₹0.00

Valuation & Enterprise Metrics Analysis: Pharmaids vs Suven Life Sciences

MetricPHARMAIDSUVEN
Price Ratios
P/E Ratio (TTM) i2,023.33-28.31
Forward P/E iN/A10.78
PEG Ratio i23.66-0.34
Price to Sales (TTM) i9.25632.35
Price to Book (MRQ) i3.3541.36
Market Capitalization
Market Capitalization i₹1.98B₹47.99B
Enterprise Value i₹2.35B₹44.90B
Enterprise Value Metrics
Enterprise to Revenue i10.98597.31
Enterprise to EBITDA i-16.22-24.12
Risk & Other Metrics
Beta i0.530.78
Book Value per Share (MRQ) i₹16.72₹5.04

Financial Statements Comparison: Pharmaids vs Suven Life Sciences

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)PHARMAIDSUVEN
Revenue/Sales i₹66.64M₹18.67M
Cost of Goods Sold i₹35.06M₹0
Gross Profit i₹31.58M₹18.67M
Research & Development iN/A₹414.88M
Operating Income (EBIT) i₹-60.16M₹-521.17M
EBITDA i₹-53.69M₹-501.49M
Pre-Tax Income i₹-71.71M₹-515.17M
Income Tax i₹-18.56M₹0
Net Income (Profit) i₹-53.15M₹-515.17M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)PHARMAIDSUVEN
Cash & Equivalents i₹21.45M₹150.26M
Total Current Assets i₹223.07M₹754.72M
Total Current Liabilities i₹287.15M₹234.86M
Long-Term Debt i₹331.19MN/A
Total Shareholders Equity i₹550.42M₹1.10B
Retained Earnings i₹-266.77M₹-6.01B
Property, Plant & Equipment i₹19.32M₹756.69M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)PHARMAIDSUVEN
Operating Cash Flow i₹-1.10MN/A
Capital Expenditures i₹0N/A
Free Cash Flow i₹2.39MN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricPHARMAIDSUVEN
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i4,989184,111
Average Daily Volume (90 Day) i4,937150,383
Shares Outstanding i35.27M218.07M
Float Shares i5.78M67.61M
% Held by Insiders i0.77%0.69%
% Held by Institutions i0.00%0.02%

Dividend Analysis & Yield Comparison: Pharmaids vs Suven Life Sciences

MetricPHARMAIDSUVEN
Last 12-Month Dividend iN/A₹0.00
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/A₹0.00
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/A₹0.00
Ex-Dividend DateN/AN/A